<?xml version="1.0" encoding="UTF-8"?>
<p>The following clinical data were obtained at diagnosis of CHC infection in no-treatment group and at time of antiviral therapy in treatment group; age (year), gender, body mass index (BMI, kg/m
 <sup>2</sup>), complete blood count, serum alanine aminotransferase (ALT, IU/L) level, prothrombin time (international normalized ratio), serum albumin or bilirubin, serum alpha-fetoprotein (AFP) level, Child-Turcotte-Pugh classification, hepatitis B surface antigen or antibody, HCV RNA (IU/mL), HCV genotype, and presence of LC. LC was clinically diagnosed based on evidence of portal hypertension (encephalopathy, esophageal varices, ascites, or splenomegaly), low platelet count (&lt;100,000/mm
 <sup>3</sup>), or liver ultrasonography (USG) findings.
 <sup>[
  <xref rid="R22" ref-type="bibr">22</xref>,
  <xref rid="R23" ref-type="bibr">23</xref>]
 </sup> SVR was defined as an undetectable HCV RNA level at 24 weeks later after completing antiviral therapy.
</p>
